Education & Training
Medical School
University of Missouri Columbia
Internship
Transitional Year
- Mercy Hospital St. Louis-GME
Residency
Dermatology
- University of Missouri School of Medicine GME
Fellowship
Dermatology
- Brigham & Womens Hospital
Boards
Insurances
MU Health Care participates with most major managed care organizations. To find out whether MU Health Care is a participating provider in your insurance plan or network, or for information on co-payments and deductibles, please contact your insurance carrier directly.
Academic Information
Office
1 Hospital Drive
MA 111
Columbia, MO 65212
United States
Research Profile
Jesse Hirner, MD is interested in complex medical dermatology, skin cancer prevention, dermatology education, access to dermatologic care.
Research Interests
- Cutaneous Oncology
- Dermatologic Oncology
Areas of Expertise
- Cutaneous Oncology
- Dermatologic Oncology
- Dermatologic toxicities from anti-cancer therapies
- Graft-versus-host disease
- Medical Dermatology
Awards & Honors
- 2021 – Present Multinational Association of Supportive Care in Cancer October
- 2020 – Present Reviewer, Journal of the American Academy of Dermatology
- 2019 – Present Diplomate, American Board of Dermatology September Massachusetts Medical Society
- 2016 – Present Medical Dermatology Society October
- 2016 – Present Fellow, American Academy of Dermatology
Publications
- Becker NV, Bakshi S, Martin KL, et al including Hirner JP.
Provider experience and satisfaction with a novel virtual team rounding program during the COVID-19 pandemic.
Int J Qual Health Care. 2021;33(3):mzab111. doi:10.1093/intqhc/mzab111 - Becker NV, Bakshi S, Martin KL, et al including Hirner JP.
Virtual team rounding: A cross- specialty inpatient care staffing program during the COVID-19 pandemic.
Acad Med. 2021. 96(12):1717-1721. doi: 10.1097/ACM.0000000000004208 - Buy AN, Singer S, Hirner J, et al.
Cutaneous connective tissue disease associated with immune checkpoint inhibitor therapy: a retrospective analysis.
J Am Acad Dermatol. 2021;84(3):864-9. doi: 10.1016/j.jaad.2020.10.054 - Bui AN, Hirner J, Singer S et al.
De novo subacute cutaneous lupus erythematosus like eruption in the setting of PD-1 or PD-L1 inhibitor therapy: clinicopathologic correlation.
Clin Exp Dermatol. 2021;46(2):328-37. doi: 10.1111/ced.14449 - Talia J, Hirner JP.
Chapter 26, BRAF inhibitors. In: Alloo A, LeBoeuf NR, editors.
Cutaneous Toxicities to Anticancer Therapies, 1st ed. Philadelphia. Wolters Kluwer. In Press. - Hirner JP, Dewan A.
Chapter 37, Programmed cell death 1 inhibitors. In: Alloo A, LeBoeuf NR, editors.
Cutaneous Toxicities to Anticancer Therapies, 1st ed. Philadelphia. Wolters Kluwer. In Press. - Hirner JP.
Chapter 6, Bites and stings. In: Walls AC editor.
Manual of Urgent and Emergent Dermatology, 1st ed. Philadelphia. Wolters Kluwer. In Press. - Bui AN, Hirner J, Singer S et al.
Cutaneous connective tissue disease associated with immune checkpoint inhibitor therapy: a retrospective analysis.
2020 Medical Dermatology Society Meeting.